Control of mineralocorticoid substitution in Addison's disease by plasma renin measurement
- PMID: 940296
- DOI: 10.1007/BF01469025
Control of mineralocorticoid substitution in Addison's disease by plasma renin measurement
Abstract
In 7 out-patients with Addison's disease, plasma renin activity (PRA), plasma concentrations of angiotensin II (AT II), renin substrate (PRS), potassium, sodium and total protein, hematocrit, blood pressure, heart rate and body weight were studied after 2 weeks each on 2 mg of dexamethasone, 25 mg hydrocortisone (HC), 25 mg HC + 0.05 mg 9-alpha-fluorohydrocortisone (FC), 25 mg HC + 0.1 mg FC and 25 mg HC + 0.2 MG FC. Four further patients were less extensively studied. Mean PRA (upper normal limit, ambulatory: 12 ng AT I-ml-1-h-1) after the 5 steps of incremental substitution, starting with dexamethasone, was 192, 59, 38, 24 and 9 ng AT I-ml-1-h-1 rsp. PRS did not change with increasing substitution. PRA and AT II were significantly correlated (r = 0.91; p less than 0.0001) and proved to be the most sensitive parameters of insufficient mineralocorticoid substitution. With decreasing significance, PRA also correlated with plasma protein concentration, plasma sodium concentration (negative), delta body weight (negative), heart rate, delta mean blood pressure (negative) and plasma potassium concentration. PRA or AT II measurements are useful clinical tools to control mineralocorticoid substitution in Addisonian patients. Inappropriately high substitution can be prevented by keeping PRA in the upper normal range.
Similar articles
-
Effects of fludrocortisone withdrawal on plasma angiotensin II, ACTH, vasopressin, and potassium in patients with Addison's disease.Acta Endocrinol (Copenh). 1987 Jul;115(3):325-30. doi: 10.1530/acta.0.1150325. Acta Endocrinol (Copenh). 1987. PMID: 3039766
-
Mineralocorticoid replacement in Addison's disease.Clin Endocrinol (Oxf). 1979 May;10(5):499-506. doi: 10.1111/j.1365-2265.1979.tb02107.x. Clin Endocrinol (Oxf). 1979. PMID: 476980
-
Atrial natriuretic peptide and plasma renin levels in assessment of mineralocorticoid replacement in Addison's disease.J Clin Endocrinol Metab. 1996 Apr;81(4):1411-5. doi: 10.1210/jcem.81.4.8636343. J Clin Endocrinol Metab. 1996. PMID: 8636343 Clinical Trial.
-
Mineralocorticoid substitution and monitoring in primary adrenal insufficiency.Best Pract Res Clin Endocrinol Metab. 2015 Jan;29(1):17-24. doi: 10.1016/j.beem.2014.08.008. Epub 2014 Aug 27. Best Pract Res Clin Endocrinol Metab. 2015. PMID: 25617169 Review.
-
Management of hypertension and heart failure in patients with Addison's disease.Clin Endocrinol (Oxf). 2015 Jun;82(6):789-92. doi: 10.1111/cen.12592. Epub 2014 Sep 16. Clin Endocrinol (Oxf). 2015. PMID: 25138826 Review.
Cited by
-
Desoxycorticosterone Pivalate Duration of Action and Individualized Dosing Intervals in Dogs with Primary Hypoadrenocorticism.J Vet Intern Med. 2017 Nov;31(6):1649-1657. doi: 10.1111/jvim.14828. Epub 2017 Sep 11. J Vet Intern Med. 2017. PMID: 28892205 Free PMC article. Clinical Trial.
-
Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline.J Clin Endocrinol Metab. 2016 Feb;101(2):364-89. doi: 10.1210/jc.2015-1710. Epub 2016 Jan 13. J Clin Endocrinol Metab. 2016. PMID: 26760044 Free PMC article. Review.
-
Diabetic and endocrine emergencies.Postgrad Med J. 2007 Feb;83(976):79-86. doi: 10.1136/pgmj.2006.049445. Postgrad Med J. 2007. PMID: 17308209 Free PMC article. Review.
-
Physiological basis for the etiology, diagnosis, and treatment of adrenal disorders: Cushing's syndrome, adrenal insufficiency, and congenital adrenal hyperplasia.Compr Physiol. 2014 Apr;4(2):739-69. doi: 10.1002/cphy.c130035. Compr Physiol. 2014. PMID: 24715566 Free PMC article. Review.
-
Adrenal insufficiency.Nat Rev Dis Primers. 2021 Mar 11;7(1):19. doi: 10.1038/s41572-021-00252-7. Nat Rev Dis Primers. 2021. PMID: 33707469 Review.
References
MeSH terms
Substances
LinkOut - more resources
Research Materials